v3.26.1
COMMITMENTS AND CONTINGENCIES (Tables)
 12 Months Ended
Apr. 30, 2026
Commitments and Contingencies Disclosure [Abstract]  
Schedule of contractual obligation, fiscal year maturity
 
Payment Due Date
$50,000*  Pre-IND Meeting - Completed September 2019
   
$65,000*  IND application filing - Completed June 2021
   
$190,000*  Upon first dosing of patient in a clinical trial - Completed December 2021
   
$500,000*  Upon completion of first clinical trial - Completed March 2022
   
$1,250,000 Upon first patient treated in a Phase III clinical trial
   
$10,000,000 Upon FDA NDA approval
*Milestone met and completed

 

ALZN002 License:

 

Payment Due Date
$50,000* Upon IND application - Completed January 2022
   
$50,000 Upon first dosing of patient in first Phase I clinical trial
   
$500,000 Upon completion of first Phase IIB clinical trial
   
$1,000,000 Upon first patient treated in a Phase III clinical trial
   
$10,000,000 Upon first commercial sale
*Milestone met and completed

 

Additional AL001 Licenses:

 

Payment Due Date
$2,000,000 Upon first patient treated in a Phase III clinical trial
   
$16,000,000 First commercial sale